Why SLS stock is jumping premarket: SELLAS Life Sciences puts REGAL Phase 3 countdown back in play
SELLAS Life Sciences shares rose 3.4% to $4.29 in premarket trading Monday after closing at $4.15 Friday. Investors are watching for the 80th event in the company’s Phase 3 AML study, which will trigger a final analysis. SELLAS reported $71.8 million in cash at year-end and recently raised $26.5 million from warrant exercises. Short interest stands at 41.33 million shares, about 24% of the float.